Katherine Lu is a Partner of LYZZ Capital. She has over 15 years of equity investment and research experience in global healthcare sectors and was one of the first analysts initiated coverage of overseas-listed Chinese healthcare stocks. Before joining LYZZ Capital, Katherine worked at Sectoral Asset Management, a global healthcare investment fund, responsible for its emerging market healthcare investment. Prior to that, Katherine served as a Managing Director at Cowen & Co, heading its China Healthcare equity research. Before that, Katherine was a Managing Director and Head of China Equity Research at Oppenheimer & Co. In addition, she also worked as a Director at CIBC World Market, covering US Specialty Pharma. Katherine started her Wall Street career as an associate analyst at SG Cowen, covering US Large-Cap Medtech. Prior to Wall Street, Katherine worked as a drug discovery scientist at Johnson & Johnson and Roche for six years, focusing on cancer therapeutics. She also worked as a healthcare management consultant at Bogart Delafield Ferrier.
Katherine holds a BS in chemistry from Nanjing University, an MS in organic chemistry from Iowa State University and an MBA from New York University Stern School of Business. Katherine is also a CFA charterholder.